Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

Poll Finds Mixed Views About Schools’ Pandemic Performance

A year into the COVID-19 pandemic, Massachusetts residents have mixed opinions about how K-12 education has functioned, but they tend to view the performance of individual teachers more favorably than that of institutions like school districts and teachers’ unions, according to a poll of 1,500 residents commissioned by Pioneer Institute.

Doctor Heal Thyself: Insider’s Prescription For Healthcare Reform

Host Joe Selvaggi talks with surgeon and New York Times bestselling author Dr. Marty Makary about the healthcare reform themes in The Price We Pay, the 2020 Business Book of the Year.  The discussion covers the value of price transparency, provider accountability, and performance information to drive better medical outcomes and improve doctor and patient satisfaction.

New Study Warns Graduated Income Tax Will Harm Many Massachusetts Retirees

If passed, a constitutional amendment to impose a graduated income tax would raid the retirement plans of Massachusetts residents by pushing their owners into higher tax brackets on the sales of homes and businesses, according to a new study published by Pioneer Institute. The study, entitled “The Graduated Income Tax Trap: A retirement tax on small business owners,” aims to help the public fully understand the impact of the proposed new tax.

Dartmouth’s Prof. Susannah Heschel Discusses Rabbi Abraham Joshua Heschel & the Civil Rights Movement

This week on “The Learning Curve," Gerard and Cara talk with Dr. Susannah Heschel, the Eli M. Black Distinguished Professor of Jewish Studies at Dartmouth College, and the daughter of noted 20th-century Jewish theologian and Civil Rights-era leader, Rabbi Abraham Joshua Heschel. They discuss what teachers and students today should know about Rabbi Heschel’s life and legacy.

Study: Graduated Income Tax Proponents Rely on Analyses That Exclude the Vast Majority Of “Millionaires” to Argue Their Case

Advocates for a state constitutional amendment that would apply a 4 percent surtax to households with annual earnings of more than $1 million rely heavily on the assumption that these proposed taxes will have little impact on the mobility of high earners. They cite analyses by Cornell University Associate Professor Cristobal Young, which exclude the vast majority of millionaires, according to a new study published by Pioneer Institute.

Hoover Institution’s Dr. Eric Hanushek on COVID-19, K-12 Learning Loss, & Economic Impact

0 Comments
/
This week on “The Learning Curve," Gerard and Cara talk with Dr. Eric Hanushek, the Paul and Jean Hanna Senior Fellow at Stanford University’s Hoover Institution. They discuss his research, cited by The Wall Street Journal, on learning loss due to the pandemic, especially among poor, minority, and rural students, and its impact on skills and earnings.

UK Classics Scholar Kathryn Tempest on Cicero, Brutus, & the Death of Caesar

This week on “The Learning Curve," Gerard and Cara talk with Dr. Kathryn Tempest, a Reader in Classics and Ancient History at the University of Roehampton in London, UK, and author of Cicero: Politics and Persuasion in Ancient Rome and Brutus: The Noble Conspirator. They discuss the historical, civic, and moral lessons political leaders, educators, and schoolchildren today can learn by studying the Roman Republic and the lives of key figures from that era such as Cicero and Brutus.

Pioneer Institute’s 2021 Government Transparency Resolutions: Sunshine Week Edition

As it does each year, Pioneer shares the resolutions it hopes state leaders will adopt to bring government actions into better focus and invigorate our democracy with heightened public engagement. As the late Supreme Court Justice Louis Brandeis noted, “sunlight is said to be the best of disinfectants; electric light the most efficient policeman.”

Traffic Strikes Back: New Transportation Strategies for Post-Pandemic Prosperity

Host Joe Selvaggi talks with Chris Dempsey, Director of Transportation for Massachusetts, about road and mass transit innovations that could address traffic challenges in a high-growth, post-pandemic economy.

Report Contrasts State Government and Private Sector Employment Changes During Pandemic

Massachusetts state government employment has been virtually flat during COVID-19 even as employment in the state’s private sector workforce remains nearly 10 percent below pre-pandemic levels, according to a new study published by Pioneer Institute. The study, “Public vs. Private Employment in Massachusetts: A Tale of Two Pandemics,” questions whether it makes sense to shield public agencies from last year’s recession at the expense of taxpayers.

Best-Selling, Netflix Author Loung Ung On Surviving Pol Pot’s Killing Fields

0 Comments
/
This week on “The Learning Curve," Gerard and Cara talk with Loung Ung, a human-rights activist; the author of the bestselling books First They Killed My Father: A Daughter of Cambodia Remembers, Lucky Child, and Lulu in the Sky; and a co-screenwriter of the 2017 Netflix Original Movie, First They Killed My Father. Ms. Ung shares her experiences living through genocide under Pol Pot and the Khmer Rouge from 1975 to 1979, which resulted in the deaths of nearly a quarter of Cambodia's population. 

Post-Pandemic Prospects: Tech Leaders’ Prescription for Preserving a Healthy Economy

0 Comments
/
Host Joe Selvaggi talks with Chris Anderson, President of the Massachusetts High Technology Council, about the reasons why Massachusetts has a thriving tech sector, what challenges his members have faced in the pandemic, and what he sees as the most prudent path toward future prosperity in the commonwealth.